Skip to Content
Merck
CN

Discovery of a potent and selective aurora kinase inhibitor.

Bioorganic & medicinal chemistry letters (2008-08-06)
Johan D Oslob, Michael J Romanowski, Darin A Allen, Subramanian Baskaran, Minna Bui, Robert A Elling, William M Flanagan, Amy D Fung, Emily J Hanan, Shannon Harris, Stacey A Heumann, Ute Hoch, Jeffrey W Jacobs, Joni Lam, Chris E Lawrence, Robert S McDowell, Michelle A Nannini, Wang Shen, Jeffrey A Silverman, Michelle M Sopko, Bradley T Tangonan, Juli Teague, Josh C Yoburn, Chul H Yu, Min Zhong, Kristin M Zimmerman, Tom O'Brien, Willard Lew
ABSTRACT

This communication describes the discovery of a novel series of Aurora kinase inhibitors. Key SAR and critical binding elements are discussed. Some of the more advanced analogues potently inhibit cellular proliferation and induce phenotypes consistent with Aurora kinase inhibition. In particular, compound 21 (SNS-314) is a potent and selective Aurora kinase inhibitor that exhibits significant activity in pre-clinical in vivo tumor models.

MATERIALS
Product Number
Brand
Product Description

Sigma-Aldrich
SNS-314 mesylate, ≥98% (HPLC)